Abstract
Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, we hypothesized that a peptide binder to the CK2 phosphoacceptor site could exhibit anticancer properties in vitro, in tumor animal models, and in cancer patients. By screening a random cyclic peptide phage display library, we identified the CIGB-300 (formerly P15-Tat), a cyclic peptide which abrogates the CK2 phosphorylation by blocking recombinant substrates in vitro. Interestingly, synthetic CIGB-300 led to a dose-dependent antiproliferative effect in a variety of tumor cell lines and induced apoptosis as evidenced by rapid caspase activation. Importantly, CIGB-300 elicited significant antitumor effect both by local and systemic administration in murine syngenic tumors and human tumors xenografted in nude mice. Finally, we performed a First-in-Man trial with CIGB 300 in patients with cervical malignancies. The peptide was found to be safe and well tolerated in the dose range studied. Likewise, signs of clinical benefit were clearly identified after the CIGB-300 treatment as evidenced by significant decrease of the tumor lesion area and histological examination. Our results provide an early proof-of-principle of clinical benefit by using an anti-CK2 approach in cancer. Furthermore, this is the first clinical trial where an investigational drug has been used to target the CK2 phosphorylation domain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baselga J (2006) Targeting tyrosine kinases in cancer. Science 312:1175–1178. doi:10.1126/science.1125951
Kantarjian HM, Cortes J (2006) New strategies in chronic myeloid leukemia. Int J Hematol 83:289–293. doi:10.1532/IJH97.06024
Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349–368. doi:10.1096/fj.02-0473rev
Johnston IM, Allison SJ, Morton JP, Schramm L, Scott P, White RJ (2002) CK2 forms a stable complex with TFIIIB and activates RNA polymerase III transcription in human cells. Mol Cell Biol 22:3757–3768. doi:10.1128/MCB.22.11.3757-3768.2002
Guerra B, Issinger O-G (1999) Protein kinase CK2 and its role in cellular proliferation, development, and pathology. Electrophoresis 20:391–408. doi:10.1002/(SICI)1522-2683(19990201)20:2≤391::AID-ELPS391≥3.0.CO;2-N
Ahmed K, Gerber DA, Cochet C (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12:226–230. doi:10.1016/S0962-8924(02)02279-1
Barz T, Ackermann K, Dubois G, Eils R, Pyerin W (2003) Genome-wide expression screens indicate a global role for protein kinase CK2 in chromatin remodeling. J Cell Sci 116:1563–1577. doi:10.1242/jcs.00352
Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108:1698–1707. doi:10.1182/blood-2005-11-013672
Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC (1998) P53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. Oncogene 16:2965–2974. doi:10.1038/sj.onc.1201854
Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE et al (2001) Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 227:153–165. doi:10.1023/A:1013108822847
Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K (2001) Protein kinase CK2 signal in neoplasia. Histol Histopathol 16:573–582
Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K (1996) Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett 101:31–35. doi:10.1016/0304-3835(96)04110-9
Serno S, Salvi M, Battistutta R, Zanotti G, Pinna LA (2005) Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 1754:263–270
Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2:712–720
Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I et al (2004) Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the Casein Kinase 2 (CK2). Cancer Res 64:7127–7129. doi:10.1158/0008-5472.CAN-04-2086
Fields R (1990) Nobel, Solid phase peptide synthesis utilizing 9-fluorenylmethoxycabonyl amino acid. Int J Pept Protein Res 35:161–214
Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O et al (2008) Systemic administration of a peptide that impairs the Protein Kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int J Cancer 122:57–62. doi:10.1002/ijc.23013
Acknowledgements
This work was supported by HeberBiotec SA and Biorec.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perea, S.E., Reyes, O., Baladron, I. et al. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol Cell Biochem 316, 163–167 (2008). https://doi.org/10.1007/s11010-008-9814-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-008-9814-5